Allergy Therapeutics Plc has received a public opening position disclosure/dealing disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics Plc, the offeror/offeree in question. The date of the position held/dealing undertaken is 28/09/23. The disclosure does not include any other party to the offer.

In terms of positions, Cavendish Securities Plc owns and/or controls 241,644 relevant securities of Allergy Therapeutics Plc, which represents 0.04% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell.

Regarding dealings, Cavendish Securities Plc has made purchases of 51,071 securities of Allergy Therapeutics Plc at a highest price per unit of 2.60 and a lowest price per unit of 1.90. There are no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings (including subscribing for new securities) disclosed.

There are no indemnity or other dealing arrangements, agreements, arrangements, or understandings relating to options or derivatives disclosed. No supplemental form 8 (open positions) is attached to the disclosure. The date of disclosure is 29/09/23, and the contact name is Angela Teodorescu with a telephone number of 02037724641.